Resources from the same session
LBA21 - FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group
Presenter: Marinde Bond
Session: Proffered Paper session 1: GI, lower digestive
Resources:
Abstract
Slides
Webcast
LBA22 - Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study
Presenter: Armando Orlandi
Session: Proffered Paper session 1: GI, lower digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA21 and LBA22
Presenter: Julien Taieb
Session: Proffered Paper session 1: GI, lower digestive
Resources:
Slides
Webcast
314O - Adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced colon cancer (HIPECT4): A randomized phase III study
Presenter: Alvaro Arjona-Sanchez
Session: Proffered Paper session 1: GI, lower digestive
Resources:
Abstract
Slides
Webcast
LBA23 - Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): The SAMCO-PRODIGE 54 randomised phase II trial
Presenter: Julien Taieb
Session: Proffered Paper session 1: GI, lower digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant 314O and LBA23
Presenter: Andrea Cercek
Session: Proffered Paper session 1: GI, lower digestive
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 1: GI, lower digestive
Resources:
Slides
Webcast